Download the full report

Annual Report 2009 Download PDF (4.56MB)

Executive management

Timothy Wright
Timothy Wright BSc PhD MBA
Commercial Director
Dr Tim Wright, 48, joined Vectura as Commercial Director in March 2005. Prior to joining Vectura he gained a breadth of experience in business development and licensing in a number of senior roles at BTG plc, latterly as Vice President Business Development and Licensing, Oncology, and as Director of Business Development at DevCo Pharmaceuticals, where he was successful in building a portfolio of neuroscience development candidates. Between 1986 and 1999 Tim held a number of management positions at GlaxoWellcome Research and Development, both in Clinical Pharmacology and Medical Operations, and in project management at Simbec Research Limited. Tim trained as a research scientist at London University, obtaining a PhD in neuroendocrinology in 1987. He was awarded an MBA from London Business School’s Executive Programme in 1994.

Martin Shott
Martin John Shott PhD MRPharmS
Pharmaceutical Operations Director
Dr Martin Shott, 57, joined Vectura as Pharmaceutical Operations Director in October 2002 with a wide range of experience from within the pharmaceutical industry. Prior to joining Vectura he worked for four years at Innovata Biomed as Associate Director of Research and Development. Martin has gained extensive experience in the UK and Europe working as a senior manager at several companies, including Lers-Synthelabo and Ciba-Geigy (later Novartis), where he managed the global DPI development unit based in the UK. He trained as a research scientist, during which time he investigated the compression of pharmaceutical powders for a PhD at Nottingham University, while continuing to work in the industry. He is a member of the Royal Pharmaceutical Society of Great Britain.

Mark Main
Mark Jonathan Main BSc PhD
Development Director
Dr Mark Main, 49, joined Vectura as Development Director in May 2004. Prior to joining Vectura he was with Powderject Pharmaceuticals, which he joined in 2001 to lead multidisciplinary development teams for both drug delivery and vaccine products involving all aspects of the drug/device development process. He was previously with Sterling Winthrop in 1986 and subsequently Parke-Davis, Ipsen International, and Scotia Pharmaceuticals, gaining extensive experience of clinical development and project management in the areas of cardiovascular and oncological treatment. Mark trained as a research scientist at St George's Hospital Medical School, where he gained his doctorate investigating the prevention of ischaemia-induced damage of the mammalian myocardium.

Stephen Eason
Stephen William Eason BSc (Eng)
Director of Device Development
Stephen Eason, 51, joined Vectura as Director of Device Development in February 2002 when the Aspirair® inhaler technology and staff were acquired from Cambridge Consultants Ltd (CCL), where he was an associate director. He had previously initiated and led the Aspirair® development programme at CCL and has subsequently initiated and led the GyroHaler® development programme for Vectura. While at CCL Stephen carried out significant product developments in the areas of inhalation, injection and infusion products. Prior to joining CCL, Stephen worked for seven years as a design and development engineer within the manufacturing industry, first with the TI Group and then with Baxter Healthcare. Stephen studied Mechanical Engineering at the Imperial College of Science and Technology, London.

Colin Dalton
Colin Clive Dalton BTech PhD
Director of Intellectual Property and Corporate Affairs
Dr Colin Dalton, 59, joined Vectura as Director of IP and Corporate Affairs in January 2007 when Innovata plc was acquired. He was previously Corporate Development Director with Innovata and Quadrant Healthcare Limited, a formulation company acquired by Innovata. For five years prior to joining Quadrant he was Director of Business Development at GSK Biologicals where he managed a group responsible for licensing new products and technologies, collaborations and alliances. He previously worked in business development at Quadrant and British Sugar plc and was a senior consultant in the biotechnology practice at PA Consulting. He started his career as a fermentation scientist at BP Co Ltd. He trained as an applied biologist at Brunel University and obtained a PhD in 1977 at Leicester University.